Cytokines and chemokines triggered by Chikungunya virus infection in human patients during the very early acute phase

Tanabe, Ithallo Sathio Bessoni; Santos, Elane Conceição dos; Tanabe, Eloiza; Souza, Stephannie Janaina Maia de; Santos, Fabio E F; Taniele-Silva, Jamile; Ferro, Jean F G; Lima, Magliones Carneiro de; Moura, Adriana Ávila; Anderson, Letícia; Bassi, Ênio José

doi:10.1093/trstmh/trz065

Cited by 8 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we found that higher levels of CXCL8 in acutephase samples of chikungunya patients was significantly associated with development of arthralgia that last >3 months. This is consistent with other studies that reported an increase in circulating levels of CXCL8 in patients with CHIKV infection (35). This specific chemokine is secreted by activated macrophages mainly during the innate immune response and promotes the recruitment of neutrophils to the inflammatory site (36).…”

Section: Discussionsupporting

confidence: 93%

“…Reddy et al (25) also found that chikungunya patients who had chronic arthralgia had elevated levels of CXCL8 in the second week after symptom onset. Several other studies have reported elevated serum CXCL8 levels in the acute phase compared to healthy controls (35,37,38), and an even greater increase in levels of this chemokine in the chronic phase of the disease compared to the acute phase (39). Furthermore, CXCL8 has also been detected in serum (40) and synovial fluid (14, 41) of patients with chronic arthralgia after CHIKV infection.…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

Acute-Phase Levels of CXCL8 as Risk Factor for Chronic Arthralgia Following Chikungunya Virus Infection

et al. 2021

View full text Add to dashboard Cite

The immunopathogenesis of chikungunya virus (CHIKV) infection and the role of acute-phase immune response on joint pain persistence is not fully understood. We investigated the profile of serum chemokine and cytokine in CHIKV-infected patients with acute disease, compared the levels of these biomarkers to those of patients with other acute febrile diseases (OAFD) and healthy controls (HC), and evaluated their role as predictors of chronic arthralgia development. Chemokines and cytokines were measured by flow Cytometric Bead Array. Patients with CHIKV infection were further categorized according to duration of arthralgia (≤ 3 months vs >3 months), presence of anti-CHIKV IgM at acute-phase sample, and number of days of symptoms at sample collection (1 vs 2-3 vs ≥4). Patients with acute CHIKV infection had significantly higher levels of CXCL8, CCL2, CXCL9, CCL5, CXCL10, IL-1β, IL-6, IL-12, and IL-10 as compared to HC. CCL2, CCL5, and CXCL10 levels were also significantly higher in patients with CHIKV infection compared to patients with OAFD. Patients whose arthralgia lasted > 3 months had increased CXCL8 levels compared to patients whose arthralgia did not (p<0.05). Multivariable analyses further indicated that high levels of CXCL8 and female sex were associated with arthralgia lasting >3 months. Patients with chikungunya and OAFD had similar cytokine kinetics for IL-1β, IL-12, TNF, IFN-γ, IL-2, and IL-4, although the levels were lower for CHIKV patients. This study suggests that chemokines may have an important role in the immunopathogenesis of chronic chikungunya-related arthralgia.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 88%

Acute-Phase Levels of CXCL8 as Risk Factor for Chronic Arthralgia Following Chikungunya Virus Infection

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The results were compared with those for healthy controls. Levels of IFN-α, IL-6, IL-8, IL-10, IFN-γ, monokine induced by gamma interferon (MIG), MCP-1 and IP-10 were significantly increased compared with controls [21]. IL-17A, IL-21, IL-22, IL-27, IL-29, and transforming growth factor-beta were measured in CHIKV patients and healthy controls.…”

Section: Secreted Cytokines and Chemokines And Severity Of Chikv Infementioning

confidence: 96%

Cytokines and Chemokines in Chikungunya Virus Infection: Protection or Induction of Pathology

2020

View full text Add to dashboard Cite

Chikungunya virus (CHIKV) infection has been commonly detected in tropical countries. The clinical manifestations of CHIKV infection are similar to those of rheumatoid arthritis. Outbreaks of CHIKV infection in Thailand have been reported, and the inductions of various cytokines and chemokines in CHIKV patients during those outbreaks have been shown. Although immune responses in CHIKV infection have been increasingly reported, the mechanisms associated with pathology induction are still not clearly understood. This review focuses on cytokine and chemokine production in CHIKV infection, in association with the severity of joint inflammation. Several cytokines and chemokines involved in the induction or regulation of inflammatory responses were shown to associate with the severe and persistent symptoms in CHIKV infection. Further studies on the difference in immune responses observed in an autoimmune disease, rheumatoid arthritis, infectious disease, and CHIKV infection, would provide additional insights useful for proper CHIKV therapy, especially in patients with severe joint pains.

show abstract

“…CCL-3 peaked during symptoms. Receptors like CXCR-3 and CCR-2 were upregulated during incubation, with CCR-2 peaking during this phase and CXCR-3 during symptoms [57][58][59]. The increased expression of T cell and macrophage surface markers aligned with higher CXCR-3 and CCR-2 levels, suggesting their role in immune cell movement to the infection site [57,59].…”

Section: Immunology Of Chikungunya Virusmentioning

confidence: 93%

Chikungunya Virus Vaccine: An Update Review

Shaikh,

Faiyazuddin,

Khan

et al. 2024

Preprint

View full text Add to dashboard Cite

Chikungunya virus (CHIKV), a single-stranded RNA virus transmitted by Aedes mosquitoes, poses a significant global health threat, with severe complications observed in vulnerable populations. The only licensed vaccine, IXCHIQ, approved by the USFDA, is insufficient to address the growing disease burden, particularly in endemic regions lacking herd immunity. Monoclonal antibodies (mAbs), explicitly targeting structural proteins E1/E2, demonstrate promise in passive transfer studies, with mouse and human-derived mAbs showing protective efficacy. The article explores various vaccine candidates, including live attenuated, killed, nucleic-acid-based (DNA/RNA), virus-like particle, chimeric, subunit, and adenovirus vectored vaccines. RNA vaccines emerge as promising candidates due to their rapid response capabilities and enhanced safety profile. The review underscores the importance of E1 and E2 proteins as immunogens, emphasising their antigenic potential. Several vaccine candidates, such as CHIKV/IRES, measles vector (MV-CHIK), synthetic DNA-encoded antibodies, and mRNA-lipid nanoparticle vaccines, demonstrate encouraging preclinical and clinical study results. In addition to identifying potential molecular targets for antiviral therapy, the study looks into the roles played by Toll-like receptors, RIG-I, and NOD-like receptors in the immune response to CHIKV. It also offers insights into novel tactics and promising vaccine candidates.

show abstract

Cytokines and chemokines triggered by Chikungunya virus infection in human patients during the very early acute phase

Cited by 8 publications

References 16 publications

Acute-Phase Levels of CXCL8 as Risk Factor for Chronic Arthralgia Following Chikungunya Virus Infection

Acute-Phase Levels of CXCL8 as Risk Factor for Chronic Arthralgia Following Chikungunya Virus Infection

Cytokines and Chemokines in Chikungunya Virus Infection: Protection or Induction of Pathology

Chikungunya Virus Vaccine: An Update Review

Contact Info

Product

Resources

About